1. Market Research
  2. > Therapy
14 reports for Salicylic Acid (page 1)

Purchase Reports From Reputable Market Research Publishers

Hypercholesterolemia - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 252 pages

ASPIRIN + LISINOPRIL + LOVASTATIN) - DRUG PROFILE (ASPIRIN + LISINOPRIL + LOVASTATIN) (ATORVASTATIN + EZETIMIBE) - DRUG PROFILE (OLMESARTAN MEDOXOMIL + ROSUVASTATIN CALCIUM) - DRUG PROFILE (OLMESARTAN MEDOXOMIL + ROSUVASTATIN CALCIUM) STOCOSIL INC NA Drug Name Company / Institu

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Salicylic Acid
  • Therapy

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • December 2016
  • 356 pages

THESE WILL LIKELY INCLUDE ANTIPLATELET AND ANTICOAGULANT DRUGS SUCH AS ASPIRIN AND WARFARIN, AMONG OTHERS.

  • Cholesterol
  • Epidemiology
  • Hospital
  • Lipid Modifying Drug
  • Salicylic Acid

Coronary Disease Global Clinical Trials Review, H1, 2020

  • $ 2500
  • May 2020
  • 299 pages

Coronary Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* Coronary Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* aspirin alone or in combination has the highest number of coronary disease ongoing clinical trials.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Salicylic Acid

Atherosclerosis Global Clinical Trials Review, H1, 2020

  • $ 2500
  • June 2020
  • 707 pages

Versus Aspirin ## Mg O. d.

  • Cardiology
  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Salicylic Acid

Arteriosclerosis Global Clinical Trials Review, H2, 2018

  • $ 2500
  • November 2018
  • 691 pages

Versus Aspirin ## Mg O. d.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • Salicylic Acid

Coronary Disease Global Clinical Trials Review, H2, 2017

  • $ 2500
  • July 2017
  • 230 pages

CORONARY DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* CORONARY DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* aspirin and undisclosed statin alone or in combination has the highest number of coronary disease ongoing clinical trials

  • Cardiology
  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Salicylic Acid

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019
  • 304 pages

Aspirin Cardio (Acetylsalicylic Acid, ## mg, Tablets Coated with Enteric-coated; Bayer Consumer Care AG, Switzerland, Manufactured by Bayer Bitterfeld GmbH, Germany) and Crestor (Rosuvastatin, ## mg, Tablets, Film-obol Chkoy; Aypier Pharmaceuticals Inc., Puerto Rico) Open Randomized Compar

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Salicylic Acid
  • Therapy

Hyperlipidemia Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020
  • 807 pages

Aspirin Cardio (Acetylsalicylic Acid, ## mg, Tablets Coated with Enteric-coated; Bayer Consumer Care AG, Switzerland, Manufactured by Bayer Bitterfeld GmbH, Germany) and Crestor (Rosuvastatin, ## mg, Tablets, Film-obol Chkoy; Aypier Pharmaceuticals Inc., Puerto Rico) Open Randomized Compar

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Salicylic Acid
  • Statins

Dyslipidemia - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 372 pages

Dyslipidemia - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2020, provides an overview of the Dyslipidemia (Metabolic ...

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Pharmaceutical
  • Salicylic Acid

Dyslipidemia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019
  • 356 pages

Dyslipidemia - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2019, provides an overview of the Dyslipidemia (Metabolic ...

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Pharmaceutical
  • Therapy

Arteriosclerosis Global Clinical Trials Review, H1, 2017

  • $ 2500
  • April 2017
  • 509 pages

Versus Aspirin ## Mg O. d.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • Salicylic Acid

Mixed Dyslipidemia Global Clinical Trials Review, H2, 2017

  • $ 2500
  • December 2017
  • 122 pages

Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK##A in Subjects with Primary Hypercholesterolemia or Mixed Dyslipidemia A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-##A-##) GDC

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Salicylic Acid

Lipid Disorders Global Clinical Trials Review, H2, 2017

  • $ 2500
  • November 2017
  • 934 pages

Aspirin in the Elderly with One or More Risk Factors of Vascular Events: JPPP Japanese Primary Prevention Project with Aspirin GDCT## NCT##, JPPP-##-##; MHLW2004-CV(Adult disease)-## Metabolic Disorders Cardiovascular Risk Factors, Cerebrovascular Disease, Diabetes, Dysl

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Salicylic Acid

Hyperlipidemia - Pipeline Review, H1 2016

  • $ 2000
  • February 2016
  • 212 pages

The compound, a novel conjugate of the essential omega-## fatty acid docosahexaenoic acid and salicylate, is being developed to treat patients with type ## diabetes.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Salicylic Acid
  • Therapy


View report >

Cardiovascular Disease Statistics in the US

  • February 2020
  • 42 pages

Case Study ### Metformin ER ## gm daily Levemir ## units at bedtime Lisinopril ## mg daily Metoprolol ## mg daily Atorvastatin ## mg daily Aspirin ## mg daily What should her BP target be?

  • Cardiovascular Disease
  • Chronic Disease
  • Lipid Modifying Drug
  • Salicylic Acid
  • United States

Pharmaceutical Markets January 2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on